|End-of-day quote - 11/26|
Starpharma Signs Sales and Distribution Agreement for Viralezetm with Admenta Italia Group10/07/2021 | 06:26pm
Starpharma announced it has signed a sales and distribution agreement for VIRALEZETM antiviral nasal spray with ADMENTA Italia Group (ADMENTA), a leading pharmaceutical retail and wholesale distribution company in Italy. The Italian OTC pharmaceutical market is the third in Europe after Germany and the UK.1 ADMENTA operates over 260 pharmacies under its LloydsFarmacia brand, including 13 parapharmacies and 50 franchising Pharmacies in Italy. ADMENTA employs around 1,400 people in Italy across both wholesale and retail, supplying over 2,500 pharmacies, parapharmacies, drugstores and hospitals. VIRALEZETM is a broad-spectrum antiviral nasal spray, applied in the nose to provide a physical barrier - between viruses and the nasal mucous membrane - that traps and irreversibly inactivates virus, including SARS-CoV-2. The antiviral agent in VIRALEZETM, referred to as SPL7013, has been shown in laboratory studies to have potent antiviral and virucidal activity in multiple respiratory viruses and multiple variants of SARS-CoV-2, including inactivation of >99.9% of the highly infectious Delta variant. VIRALEZETM antiviral nasal spray is registered in Europe and India, and available in certain markets online. In the UK VIRALEZETM is partnered with LloydsPharmacy, also part of the McKesson group, and Starpharma is in advanced discussions with potential commercial partners elsewhere in Europe, India, Asia and other regions. VIRALEZETM is not registered for sale or supply in Australia.
© S&P Capital IQ 2021
All news about STARPHARMA HOLDINGS LIMITED